| | For the treatment or prophylaxis of institutionalized individuals during confirmed outbreaks due to influenza A or Influenza B when the predominant circulating strain is resistant to oseltamivir or for the prophylaxis of influenza A, where new cases have developed despite amantadine prophylaxis.
The outbreak must be confirmed by Public Health. |
| 414 | For treatment: 2 inhalations of 5mg (10mg) bid for 5 days, |
| | LU Authorization Period: 1 year |
| 415 | For prophylaxis: 2 inhalations of 5mg (10mg) once daily for 10 days. |
| | LU Authorization Period: 1 year |
